Epoprostenol
Epoprostenol
Definition
An oral prostacyclin and a metabolite of arachidonic acid with antihypertensive and platelet inhibitory properties. Epoprostenol binds to prostacyclin receptors on platelet surfaces, subsequently activating platelet membrane adenyl cyclase and resulting in increased cAMP levels. The elevated cAMP triggers signal transduction that leads to vasodilations. In addition, this agent also functions as an antagonist of thromboxane A2, thereby resulting in direct vasodilation of pulmonary and systemic arterial vascular beds, and inhibition of platelet aggregation.
Also known as EPOPROSTENOL — per NCIT
Also identified as
- ATC B01AC09 per RXNORM
- NCIT NCIT:C61748 per NCIT
- SCTID 108593000 per RXNORM
- SCTID 372513003 per RXNORM
- UNII DCR9Z582X0 per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Adult acute respiratory distress syndrome | may treat | MEDRT · Public domain (U.S. Government work) |
| Arteriosclerosis disorder | may treat | MEDRT · Public domain (U.S. Government work) |
| Peripheral vascular disease | may treat | MEDRT · Public domain (U.S. Government work) |
| Pulmonary hypertension | may treat | MEDRT · Public domain (U.S. Government work) |
| Purpura | may treat | MEDRT · Public domain (U.S. Government work) |
| Systemic sclerosis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Artery | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.